Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Metrics to compare | TVGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTVGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.6x | −3.3x | −0.5x | |
PEG Ratio | −0.07 | 0.00 | 0.00 | |
Price/Book | −12.5x | 1.7x | 2.6x | |
Price / LTM Sales | - | 16.8x | 2.9x | |
Upside (Analyst Target) | - | 231.6% | 45.8% | |
Fair Value Upside | Unlock | 7.2% | 8.6% | Unlock |